Documents (Page 10)

March 25, 2015

Call to Action to All Stakeholders Managing Elderly AFib Patients

On October 16, 2014 the Alliance for Aging Research convened a symposium to discuss those factors leading to the undertreatment of elderly AFib patients and to identify gaps in current clinical practice, outreach, education,  research, and policy. Read the full whitepaper to see the complete set of recommendations.
March 11, 2015

FY 2016 L-HHS Alzheimer’s Disease Letter

The Alliance for Aging Research, USAgainstAlzheimer's, Cure Alzheimer's Foundation, BrightFocus Foundation, Leaders Engaged on Alzheimer's Disease, Alzheimer's Foundation of America, and American Academy of Neurology signed on to letters submitted to the House & Senate Labor, Health  and Human Services and Education and Related Agencies (L-HHS) Subcommittees, urging for a minimum of $2 billion for Alzheimer's disease and related dementias research supported by the National Institutes of Health (NIH).
March 10, 2015

S-FAR FY 2016 Appropriations Letter

The Alliance for Aging Research signed on to an U.S. Stakeholder Forum on Antimicrobial Resistance (S-FAR) submitted to the House and Senate Committees on Appropriations urging for more resources in combating antimicrobial resistance. 
March 4, 2015

Medicare Part D Non-Interference Letter

The Alliance for Aging Research signed a letter expressing opposition to proposals that would allow the Secretary of Health and Human Services (HHS) to interfere in private prescription drug negotiations in the Medicare Part D program.
February 10, 2015

ACT-AD 21st Century Cures Letter

Accelerate Cure/Treatments for Alzheimer’s Disease (ACT-AD) submitted a letter the House Committee on Energy and Commerce to provide feedback on the 21st Century Cures discussion draft released on January 27, 2015.    
February 10, 2015

21st Century Cures Feedback Letter

The Alliance for Aging Research submitted a feedback letter on the 21st Century Cures discussion draft released on January 27, 2015 to Chairman Upton and Ranking Member DeGette.
February 6, 2015

Con. Res. Supporting Quality of Life for Prostate Cancer Patients Support Letter

The Alliance for Aging Researched signed on to a Urology Policy Forum (UPF) letter expressing support for Con. Res., the Supporting Quality of Life for Prostate Cancer Patients. 
January 30, 2015

Letter to Hatch and Bennet in Support of the Promise for Antibiotics and Therapeutics for Health (PATH) Act

This letter was from various organizations, including the Alliance for Aging Research, to Sen. Orrin Hatch and Sen. Michael Bennet to "express support for S. 185, the Promise for Antibiotics and Therapeutics for Health (PATH) Act, legislation to establish a new limited population antibacterial drug approval pathway for antibiotics to treat serious or life-threatening infections for which there exists an unmet medical need."
January 1, 2015

Atrial Fibrillation Survey Report–Insights and Analysis

A survey of more than 500 adults with atrial fibrillation age 65 and over, explored first diagnosis, referrals, their treatment decision process, anticoagulant use, medication switching, bleeding complications, and more.
December 15, 2014

Exploring Scientific Evaluation and Intake Recommendations of Bioactive Compounds and the Public/Private Path to Get There – Meeting Summary

On October 23, 2014, the Alliance for Aging Research, with support from Mars, Inc., convened key stakeholders from the Institute of Medicine (IOM) and other non-profit organizations, the U.S. and Canadian Governments, academia, and private industry to discuss scientific evaluation of bioactive compounds. Dr. Joanne Lupton, Distinguished Professor of Nutrition at Texas A&M University, co-chaired the meeting with Susan Peschin, President and CEO of the Alliance for Aging Research, and described the goals of the meeting as follows: (1) to identify concrete ideas for creating an evaluation process for bioactives, including intake recommendations, and (2) to address issues with and opportunities for public-private partnerships. She also shared a working definition of bioactive compounds and suggested it be used for the discussion: Bioactives, according to the working definition, are “constituents in foods or dietary supplements, other than those needed to meet basic human needs, which are responsible for changes in health status.” The meeting included four presentations that helped frame the discussion. These presentations were on perspectives from the Subcommittee on Dietary Reference Intakes (DRIs), application of the DRI paradigm to bioactives, lessons learned from research on cocoa flavanols, and development of public-private partnerships. Download the full meeting summary to learn more.